An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Registration Number
- NCT01488331
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 217
Inclusion Criteria
- Adult patients, >/=18 years of age
- Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV)
- Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start
Read More
Exclusion Criteria
- Not agreeing to be followed-up (for a maximum of 24 months)
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival 24 months
- Secondary Outcome Measures
Name Time Method Overall survival 24 months Treatment compliance of patient 24 months Best treatment response 24 months Safety (incidence of adverse events) 24 months Type of treatment response 24 months